CVRx Appoints Industry Veteran Kevin Hykes to Board of Directors
(NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022.
- (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022.
- “We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors,” said John Nehra, lead independent director of CVRx.
- Prior to joining Augmedics, Kevin was President and CEO of Bardy Diagnostics, which was acquired by Hillrom in August of 2021.
- “I am honored to join the CVRx Board of Directors,” said Mr. Hykes.